Advanced in Metastatic Brain Tumor

Andreas F. Hottinger

Lausanne, VD, CH 
Advanced in Metastatic Brain Tumor
Lausanne, VD, CH 
OverviewLocationsClinical Research

Overview

Andreas Hottinger practices in Lausanne, Switzerland. Mr. Hottinger is rated as an Advanced expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Glioma, Gliomatosis Cerebri, Astrocytoma, Awake Craniotomy, and Posterior Fossa Decompression.

His clinical research consists of co-authoring 99 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Lausanne, VD 1011, Switzerland
Other Locations
Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneve, GE, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study
IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study
Enrollment Status: Terminated
Publish Date: February 01, 2022
Intervention Type: Radiation, Drug, Procedure
Study Drug: Temozolomide
Study Phase: Phase 3
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
Enrollment Status: Terminated
Publish Date: May 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

99 Total Publications

Radiosurgery of benign intracranial lesions. Indications, results , and perspectives
Radiosurgery of benign intracranial lesions. Indications, results , and perspectives
Journal: Revue medicale suisse
Published: May 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hottinger's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile